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and a moderate increase in A10BD (Biguanides and sulfonamides
in combination) in 2001 (0.07) and in 2006 (1.41) in term of
DID can be seen from this analysis. Financial expenditures for
antidiabetics were (in 1996 (€9,772,000), in 2001 (€18,169,000)
and in 2006 (€26,541,000). CONCLUSION: Inseparable com-
ponents of the Slovak drug policy must be viewed realistically
with regard to the antidiabetics’ consumption. Adherence to
principles of diabetes mellitus treatment’s guidelines lead to fun-
damental short and long term ﬁnancial savings within health care
systems.
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OBJECTIVE: In the treatment of type 2 diabetes (T2D), achiev-
ing glucose control often requires multiple therapies. The class of
antidiabetic agents called incretin mimetics offers an alternative
mechanism to diabetes management. This work describes the
baseline demographic and clinical characteristics of a T2D popu-
lation in a primary care setting before they initiated treatment
with the incretin mimetic, exenatide. METHODS: Patients were
extracted from the General Electric (GE) electronic medical
record (EMR) database from January 1, 2000 through June 30,
2007. Patients with T2D (diagnosis, oral antidiabetic drug pre-
scription, two consecutive fasting blood glucose levels 126 mg/
dL, or A1C 7.0%) were identiﬁed, as were those with at least
one prescription for exenatide. Using these data, descriptive sta-
tistics were calculated for these populations. RESULTS: Of the
11,601 patients with a prescription for exenatide, nearly all had
T2D (96%). A total of 7425 of the patients with a prescription of
exenatide were 18 years of age and had at least 395 days of
records prior to the index date. Compared to the 510,623 T2D
patients on other treatments with these same age and records
restrictions in the GE EMR, those patients on exenatide were
signiﬁcantly heavier (204.2 lbs. vs. 244.2 lbs. (p < 0.001)) with
higher BMI (32.9 kg/m2 vs. 38.7 kg/m2 (p < 0.001)). A larger
percentage of the exenatide population was obese or extremely
obese than the population on other treatments (89% vs. 61%
(p < 0.001)). The portion of the exenatide population with base-
line A1C 9.0 was higher than that of the population on other
treatments (56% vs. 12% (p < 0.001)) and, compared to the
total, exenatide patients had signiﬁcantly higher mean A1Cs
(7.2% vs. 8.1% (p < 0.001)). CONCLUSION: These results
suggest that exenatide is being added to T2D treatment regimens
in obese patients with relatively high A1C levels to achieve better
diabetes control.
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OBJECTIVE: To assess the extent of, exposure to, and medica-
tion expenditure trends associated with insulin-treated patients
reaching the Medicare Part D standard beneﬁciary prescription
coverage gap (i.e., ‘doughnut hole’) and catastrophic coverage.
METHODS: Patients receiving various insulin formulations and
mixtures throughout 2006 were investigated via a prescription
transaction-level retrospective database that captured 50% of all
retail dispensing activity within the U.S. Analyses focused upon
the coverage gap and catastrophic coverage within standard ben-
eﬁciaries regarding: 1) the number of patients entering; 2) the
month of entry; and 3) medication expenditures. RESULTS:
Overall, 324,430 Medicare beneﬁciaries received an insulin
regimen in 2006, consisting of 41% dual-eligibles (n = 131,611),
32% low-income subsidiaries (n = 105,151), and 27% standard
beneﬁciaries (n = 87,668). Across all coverage groups, oral
antidiabetic agents and insulin comprised 66–72% of monthly
drug expenditures. Of those potentially being exposed to a cov-
erage gap, 46% reached the ‘doughnut hole’ (12% of all Part D
beneﬁciaries) and 12% entered catastrophic coverage (3% of all
Part D beneﬁciaries). Among the near 55,300 standard beneﬁ-
ciaries (63% of 87,668) enrolling in Part D by March 2006,
prescription expenditures peaked in the month prior to entering
the coverage gap, followed by an immediate 20–25% drop in the
month thereafter. Decreased expenditures broadly corresponded
to a decrease in the number of diabetes agents dispensed. CON-
CLUSION: This analysis found that 46% of all insulin-treated
patients covered by the Medicare Part D standard beneﬁt (12%
of all Part D beneﬁciaries) were exposed to the coverage gap in
2006, characterized by a shifting of full ﬁnancial responsibility to
beneﬁciaries for outpatient medications. Entry was followed by a
20–25% decrease in expenditures and, more generally, in the
number of diabetes agents received. These ﬁndings warrant
continued evaluation of coverage policies and any subsequent
cost-shifting or deferrals in care that may occur, particularly for
chronic diseases.
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OBJECTIVE: Use of adjunctive insulin therapy with oral anti-
hyperglycemic agents in patients with type 2 diabetes (T2D) has
been growing in the US following demonstration in the U.K.
Prospective Diabetes Study that intensive therapy regimens
increased glycemic control and reduced microvascular complica-
tions. The primary objective in this study was to compare the
effect of analog insulin with human insulin usage on all-cause
and diabetes-attributable direct health care costs and utilization
in patients with type 2 diabetes. METHODS: Using the
MarketScan Research Database, commercially insured patients
were selected who initiated insulin therapy with analog or human
insulins during 2001–2005, had no insulin claims 12 months
prior to starting therapy, and a type 2 diabetes diagnosis during
the study period. Patients were followed 12-months from insulin
therapy initiation, and were stratiﬁed according to their therapy
as receiving analog insulin only (n = 18,205), human insulin only
(n = 7035), or both analog and human insulins (n = 5040).
Health care utilization and expenditures were compared between
treatment groups and between pre-index and post-index periods.
Generalized multi-valued propensity score weighting was used to
control for observable differences in distributions of pretreat-
ment variables among treatment groups. RESULTS: Although
mean costs for insulin and other prescriptions were lowest for
patients receiving only human insulin, mean post-index total
all-cause health care costs for analog insulin patients ($17,059)
Abstracts A237
were signiﬁcantly lower compared to human insulin only patients
($20,709, p < 0.001) and those receiving both analog and human
insulins ($28,679, p < 0.001). Inpatient visits, length of stay,
emergency visits, and clinic visits were also signiﬁcantly lower
(p < 0.001) for analog-only patients. Hypoglycemia-related costs
and utilization and overall diabetes-related utilization followed
the same patterns. CONCLUSION: Patients receiving only
analog insulin had higher insulin costs but lower post-index total
health care costs and utilization, whether all-cause or diabetes-
related, compared to patients receiving human insulin or a com-
bination of analog and human insulins.
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OBJECTIVE: Anemia is a well known complication associated
with CKD. However, there are little data regarding its association
with hospitalizations. The purpose of this study was to investi-
gate whether anemia is associated with increased hospitalization
costs in patients with diabetes and chronic kidney disease (CKD).
METHODS: An analysis of medical claims and laboratory data
between January 2000 and February 2006 from over 45 health
plans contributing to the Ingenix Impact National Managed Care
Database was conducted. Inclusion criteria were 2 hemoglobin
(Hb) values, 2 claims (within a 90-day period) for diabetes
mellitus preceding 1 claim for CKD and 2 glomerular ﬁltra-
tion rate values of <60 mL/min/1.73 m2, and not yet on dialysis.
Patients were excluded if they had cancer or lupus, received
organ transplantation or chemotherapy, or were treated for
anemia with an erythropoiesis-stimulating agent or blood trans-
fusions. An open-cohort design was used to classify patients
into observation periods of anemia (Hb < 11 g/dL), within the
K/DOQI treatment recommendations, and non-anemia, which
allowed for changes in anemia status over time. Both univariate
and multivariate analyses were conducted to compare periods of
anemia and non-anemia for average yearly hospitalization costs.
RESULTS: A total of 708 patients with diabetes and CKD
formed the study population. Mean age was 65 years; 44%
women. Anemia was associated with a signiﬁcant increase in
hospitalization costs, with an unadjusted incremental yearly cost
of $17,072 (anemia: $25,342; non-anemia: $8270; p < .001)
relative to non-anemia. The majority of hospitalizations (57%)
were related to cardiovascular disease, with anemia increasing
the cost of cardiovascular-hospitalizations by $8647 (anemia:
$13,723; non-anemia: $5076; p < .001). After controlling for
covariates, anemia remained signiﬁcantly associated with a hos-
pitalization cost increase. CONCLUSION: The current study
based on real-life practice data demonstrated that anemia in
patients with diabetes and CKD was associated with a signiﬁcant
increase in hospitalization costs.
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OBJECTIVE: To measure the effects of a pharmacist-run medi-
cation management program on medication adherence, glycemic
control, and total health care expenditures. METHODS: Scott
& White Health Plan (SWHP) claims data were evaluated to
identify high-risk diabetics aged 18–63 years, deﬁned as those
who demonstrate poor glycemic control (HbA1c >7.5%) and
utilized >$600 of prescription medications the year prior to
study enrollment. A control group was identiﬁed who met the
same inclusion criteria, but who were not invited to the program
due to geographic constraints. Medical utilization costs were
analyzed beginning one year prior to study enrollment and
included inpatient, outpatient, emergency department, and pre-
scription costs. Health system charges, standardized to 2006
dollars, were used as a surrogate for costs. Intervention costs
were estimated from pharmacists’ wage rates. Medication adher-
ence was calculated as medication possession ratio (MPR) of
oral antidiabetic agents. HbA1c results were analyzed to deter-
mine glycemic control. RESULTS: Analysis of 46 subjects and
their matched controls one year after program implementation
showed positive trends, although none of the results were sta-
tistically signiﬁcant. The mean MPR for the intervention group
increased from 0.69 to 0.79, while there was no change from a
baseline of 0.64 for controls [p = 0.24]. Intervention patients
demonstrated a greater improvement (9.5% to 8.2%) in HbA1c
than controls (9.5% to 8.7%) [p = 0.15]. Although total
monthly health care costs increased in both the intervention
($1448 to $1756; difference = $308  $2016) and control
groups ($1089 to $1745; difference = $656  $2641) [p = 0.46],
the increase was lower in the intervention group. CONCLU-
SION: Patients in the intervention group trended toward better
medication adherence and a greater decline in HbA1c than con-
trols. We expect the trend of cost savings will continue and
strengthen in the future due to long-term beneﬁts associated with
sustained glycemic control.
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OBJECTIVE: Patient and provider “psychological insulin resis-
tance” can contribute to a delay in initiation of insulin therapy
in patients with type 2 diabetes (T2DM). Consequently, by the
time patients initiate insulin, complications may have already
developed. If patients initiate insulin but therapy is not intensi-
ﬁed to reach glycemic goal (HbA1c 7%), the ability to prevent
or delay complications may be compromised. The objective of
this study was to determine differences in the incidence of com-
plications of diabetes between patients with HbA1c <7% and
those with HbA1c 7%. METHODS: US health claims and
clinical laboratory data from 2003–2005 were used to identify
and stratify patients by mean HbA1c (controlled 7% vs. sub-
optimally controlled 7%) for analysis. Cohort was limited to
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